IP Library Granted Patent US 11,241,469
Granted Patent B2
US 11,241,469 · App. 14/843,236 · Granted Feb 8, 2022

Active ingredient obtained from

Inventor: Jean Paufique (Objat, FR)
Assignee: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE
A61K36/28A61K8/9789A61K9/0014A61Q19/00A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,469
App. No.
14/843,236
Granted
Feb 8, 2022
Kind
B2
Abstract

The use of an active ingredient obtained from Calendula officinalis flowers as a product with topical application on the skin in the prevention or treatment of cutaneous manifestations caused by an imbalance of the epigenome in skin cells. Also, a hydrolyzate of Calendula officinalis flowers including oligosaccharides with a degree of polymerization of between 2 and 10, of fructose and glucose, with the compositions including it, and a cosmetic skin-care process.

Claims (13)

1. A hydrolyzate of Calendula officinalis flowers comprising oligosaccharides with a degree of polymerization of between 2 and 10, consisting of fructose and glucose, wherein the hydrolyzate is an enzymatic hydrolyzate, and wherein the hydrolyzate contains neither polyphenols nor terpenes.

2. The hydrolyzate according to claim 1 , wherein the hydrolyzate contains at least 2.5% oligosaccharides with a degree of polymerization of between 2 and 10, consisting of fructose and glucose.

3. The hydrolyzate according to claim 1 , wherein the hydrolyzate contains at least 13% sugars.

4. A method of boosting the epigenome in skin cells, comprising topically applying on the skin of a subject in need there of an effective amount of an active ingredient obtained from Calendula officinalis flowers, wherein the active ingredient is an enzymatic hydrolyzate of Calendula officinalis flowers, wherein the active ingredient contains neither polyphenols nor terpenes.

5. The method according to claim 4 , wherein boosting the epigenome in the skin cells comprises regulating modifications of chromatin of the skin cells.

6. The method according to claim 5 , wherein boosting the epigenome in the skin cells comprises preventing modifications of histones H3K9 and H2AX in the skin cells.

7. The method according to claim 4 , wherein boosting the epigenome in the skin cells comprises regulating expression of miRNA in the skin cells.

8. The method according to claim 7 , wherein boosting the epigenome in the skin cells comprises regulating expression of miR-29a, miR-29b, miR-22, miR-424, miR-199a in the skin cells.

9. The method according to claim 4 , wherein the enzyme hydrolysate comprises oligosaccharides with a degree of polymerization of between 2 and 10, consisting of fructose and glucose.

10. A cosmetic composition, comprising at least 0.5% by weight of dry material of the hydrolyzate according to claim 1 .

11. The cosmetic composition according to claim 10 , wherein it comprises between 0.5 and 10% by weight of dry material of the hydrolyzate.

12. A cosmetic skin-care process for combating the effects of cutaneous aging, comprising applying on the skin of a subject in need thereof an effective amount of the hydrolyzate according to claim 1 or a cosmetic composition comprising at least 0.5% by weight of dry material of the hydrolyzate.

13. A cosmetic skin-care process for having at least one effect selected from the group consisting of increasing the elasticity and tone of the skin, for smoothing the microrelief, improving the homogeneity and the surface grain of the skin, and imparting a more youthful appearance, comprising applying on the skin of a subject in need thereof an effective amount of the hydrolyzate according to claim 1 or a cosmetic composition comprising at least 0.5% by weight of dry material of the hydrolyzate.

Assignments (2)
CHANGE OF ADDRESS Recorded Jan 28, 2025
From: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE
To: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE
Reel/Frame 070028/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2015
From: PAUFIQUE, JEAN
To: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE
Reel/Frame 037185/0706 →
Priority Claims (1)
FR 14 58348 · Sep 5, 2014 · national
Continuity (1)
Related Publication 20160074455A1 · Mar 17, 2016